Wharton's Jelly MSC Isolation and Expansion Protocols
Detailed methodology for the isolation, characterization, quality control, and large-scale expansion of Wharton's Jelly-derived mesenchymal stem cells for clinical applications.
Explant
Isolation Method
Hypoxia 3%
Culture Condition
P5 (34× fold)
Expansion Capacity
7-Point Panel
QC Tests
Isolation Protocol
Umbilical cords are collected from healthy, full-term deliveries following informed consent. Cords are processed within 4 hours of delivery under GMP-compliant conditions. The Wharton's jelly matrix is separated from the umbilical vessels and amniotic membrane, then processed using an optimized explant method that preserves cell viability while maintaining high yield.
Cells are cultured in xeno-free, serum-free media supplemented with human platelet lysate (hPL) under 3% O₂ hypoxic conditions, which has been shown to enhance proliferative capacity, paracrine secretion, and immunomodulatory potency compared to standard normoxic (21% O₂) culture.
Expansion Kinetics: Hypoxia vs. Normoxia (Fold Increase)
Isolation Method Comparison
Immunophenotyping: Surface Marker Expression
| Marker | Expression (%) | ISCT Requirement | Status |
|---|---|---|---|
| CD73 | 99.2% | >95% | ✓ Positive |
| CD90 | 98.7% | >95% | ✓ Positive |
| CD105 | 97.4% | >95% | ✓ Positive |
| CD34 | 0.3% | <2% | ✓ Negative |
| CD45 | 0.5% | <2% | ✓ Negative |
| CD14 | 0.2% | <2% | ✓ Negative |
| HLA-DR | 1.1% | <2% | ✓ Negative |
Quality Control Release Panel
| Test | Specification | Result |
|---|---|---|
| Sterility (USP <71>) | No growth at 14 days | Pass |
| Endotoxin (LAL) | <5 EU/kg | 0.8 EU/kg |
| Mycoplasma (PCR) | Not detected | Not detected |
| Karyotype Analysis | Normal 46,XX or 46,XY | Normal |
| Viability (Trypan Blue) | >90% | 97.2% |
| Cell Count Accuracy | ±10% | ±4.3% |
| Tri-lineage Differentiation | Confirmed | Confirmed |
Key Conclusions
- •Explant isolation produces the highest viability (97.8%) and maintains superior stemness characteristics.
- •Hypoxic culture (3% O₂) yields a 2.2× greater expansion capacity by passage 5 vs. normoxia.
- •All batches consistently meet ISCT minimal criteria for MSC identification.
- •Xeno-free, hPL-supplemented media eliminates risks associated with fetal bovine serum.
- •Comprehensive 7-point QC panel ensures safety, sterility, and potency of every batch released for clinical use.
Selected References
- Dominici M, et al. Minimal criteria for defining multipotent mesenchymal stromal cells. Cytotherapy. 2006;8(4):315-317.
- Batsali AK, et al. Mesenchymal stem cells derived from Wharton's Jelly of the umbilical cord. World J Stem Cells. 2013;5(2):43-56.
- Mushahary D, et al. Isolation, cultivation, and characterization of human mesenchymal stem cells. Cytometry A. 2018;93(1):19-31.
Ready to Explore Your Treatment Options?
Schedule a free, no-obligation consultation with our regenerative medicine specialists. We treat patients from over 40 countries.
Or call directly: +90 534 856 92 92